THE MTOR PATHWAY ACTIVATION PREDICTS A SHORT TIME TO PROGRESSION AND OVERALL SURVIVAL IN RELAPSED MULTIPLE MYELOMA PATIENTS

被引：0
|
作者：
Guglielmelli, T. [1 ]
Merlini, R. [1 ]
Giugliano, E. [1 ]
Saglio, G. [1 ]
Brunetto, V. [1 ]
Cappia, S. [1 ]
Bacillo, E. [1 ]
Berruti, A. [1 ]
Gay, F. [2 ]
Papotti, M. [1 ]
Palumbo, A. [2 ]
机构：
[1] AUO San Luigi Gonzaga, Orbassano, Italy
[2] ASO S Giovanni Battista Osp Molinette, Turin, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0369
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [1] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
  • [2] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [3] PROGNOSTICATION OF RESPONSE TO BORTEZOMIB, PROGRESSION FREE AND OVERALL SURVIVAL IN RELAPSED/REFRACTORY MYELOMA PATIENTS
    Kyrtsonis, M. C.
    Vassilakopoulos, T. P.
    Sachanas, S.
    Panagoulias, G.
    Bartzis, V.
    Anargyrou, K.
    Dimou, M.
    Tzenou, T.
    Masouridis, S.
    Kalpadakis, C.
    Dimitrakopoulou, E.
    Kokoris, S. I.
    Dimitriadou, E.
    Siakantaris, M. P.
    Angelopoulou, M. K.
    Panayiotidis, P.
    Pangalis, G. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 263 - 263
  • [4] Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy
    Migkou, Magdalini
    Kastritis, Efstathios
    Roussou, Maria
    Gkotzamanidou, Maria
    Gavriatopoulou, Maria
    Nikitas, Nikitas
    Mparmparoussi, Despina
    Matsouka, Charis
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (04) : 323 - 329
  • [5] Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy.
    Kastritis, Efstathios
    Roussou, Maria
    Gavriatopoulou, Maria
    Migkou, Magdalini
    Gkotzamanidou, Maria
    Iakovaki, Marina
    Efstathiou, Eleni
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2010, 116 (21) : 1251 - 1251
  • [6] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    BLOOD, 2023, 142
  • [7] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [8] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
  • [9] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Siegel, David S.
    Dimopoulos, Meletios A.
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej
    San-Miguel, Jesus
    Obreja, Mihaela
    Blaedel, Julie
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
  • [10] Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone
    Harousseau, J. L.
    Nagler, A.
    Sonneveld, P.
    Blade, J.
    Hajek, R.
    Spencer, A.
    Robak, T.
    Xiu, L.
    Zhuang, S. H.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345